Navigation Links
Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
Date:9/20/2013

SALT LAKE CITY, Sept. 20, 2013 /PRNewswire-iReach/ -- On September 4th Dr. Phillip C. Hoopes, Jr., a surgeon at Hoopes Vision, successfully placed a light adjustable intraocular lens implant in a cataract patient as part of a new FDA clinical study. The surgery, which took place at Hoopes Vision's on-site surgery center, EyeSurg of Utah, was the first of its kind to take place in Utah. Dr. Hoopes said, "It was an honor to be the first in our state to implant this revolutionary new lens. At Hoopes Vision, we always strive to bring the newest and most promising technology to patients here in Utah, and this lens may change the way cataracts are treated."

The Light Adjustable Lens (LAL®) is designed to be the world's first and only intraocular lens that allows surgeons to change the power of the lens after it has been implanted in the patient's eye during a cataract surgery procedure.

Cataract development is a normal part of aging and typically results in a clouding of the natural lens of the eye, thereby negatively affecting vision. This problem is solved by removing the cataract via a surgical procedure in which the cataract is replaced by a clear synthetic lens, referred to as an intraocular lens. Currently, no commercially available lens in the world has the ability to be adjusted after implantation in the eye, and therefore, many patients still need glasses after surgery for optimal vision. The LAL is designed to give patients excellent distance vision without the need for glasses.

The LAL is currently commercially available in Europe and Mexico. However, before the LAL can be made available to patients in the U.S. it must be approved for sale by the FDA. This requires completion of a series of clinical studies, the third and final phase of which has recently commenced. The study involves the treatment of 600 eyes at 15 investigative sites across the country.

Hoopes Vision is excited to be one of these exclusive sites currently enrolling patients for the phase III study and welcomes interest in participation from prospective patients. If you'd like more information and to determine if you might qualify for the study, please contact the Hoopes Vision Clinical Research Center at (801) 988-7342.

Caution: The LAL is an investigational device and is limited by United States federal law to investigational use only.

# # #

If you'd like more information, please call the Hoopes Vision Clinical Research Center at (801) 988-7342 or email research@hoopesvision.com.

Media Contact: Steve Linn, Hoopes Vision, (801) 988-7342, research@hoopesvision.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Hoopes Vision
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Deputy HHS Secretary, Investors and Entrepreneurs to Share Their Vision of Upcoming New Era in Health Care
2. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
3. Hubble Telemedical Welcomes Healthcare Visionary Jonathan Lord, M.D. to Its Board of Directors
4. RainTree Oncology Expands Management As Strategic Vision For Community Oncology Unfolds
5. Users of PediaVisions Spot Vision Screener Honor Childrens Eye Health and Safety Month with Back-to-School Screenings
6. CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
7. Dr. Sheldon Pinnell, The Founding Father Of Topical Antioxidants, Leading Scientist Behind SkinCeuticals, And Chief Emeritus Of The Division Of Dermatology At Duke University, Dies At 76
8. CMS Proposes Permanent Medicare Payment for VisionCares Telescope Implant for Macular Degeneration
9. Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk
10. New Vision Hope For Millions Undergoing Cataract Surgery
11. Industry Veteran, John Maroney, to Join ForSight VISION5 as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... May 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of ... Canadian Intellectual Property Office has granted Oramed a ... of Exenatide". The patent covers Oramed,s invention of ... GLP-1 is an incretin hormone that stimulates the ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National Council on ... to announce the organization’s Certified Strength Coach credential has earned accreditation from the ... program validates the competency of qualified candidates for jobs in the Strength and ...
(Date:5/23/2017)... ... 23, 2017 , ... The Gallery of Cosmetic Surgery, founded ... to announce a new treatment option called Vivace Microneedling. This treatment option is ... body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, best-in-class ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and ... in Las Vegas, NV, and the importance of treating it immediately. They ... leading care for peri-implantitis, with or without a referral. As experienced periodontists and ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... chat as a standard feature on its secure clinical communication platform. The platform ... to video depending on the type and urgency of a situation. , ...
Breaking Medicine News(10 mins):